Perforation cornéenne sous chimiothérapie inhibiteur des tyrosines kinases : REGORAFENIB

Lanfant, L.; Trone, Marie Caroline; Garcin, T.; Gauthier, Angela; Thuret, Gilles; Gain, Philippe

doi:10.1016/j.jfo.2020.06.053

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASP-5878, which targets EGFR, VEGFR, RET and SRC kinases, can cause swirling deposits in the cornea, resulting in blurred vision ( 42 ). The multi-target TKI inhibitor regorafenib ( 43 ) is mainly anti-VEGF and can cause severe corneal perforation. In addition, the FGFR-TKI infigratinib ( 44 ) can cause dry eye, severe punctate keratitis, and recurrent corneal ulcers.…”

Section: Discussionmentioning

confidence: 99%

Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report

Xiang,

Lin,

Guan

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Programmed cell death-1 (PD-1) inhibitors and anti-angiogenic drugs have become a hotspot in research of anti-tumor programs; however, they can also cause some rare drug-related adverse reactions. Immune checkpoint inhibitors (ICIs) cause adverse reactions in the body, collectively known as immune-related adverse events (irAEs). Ocular side effects can occur in both targeted and immunotherapy patients, including dry eye, blurred vision, uveitis, conjunctivitis, retinopathy, or thyroid eye disease. To our knowledge, this is the first case report describing corneal ulcers secondary to dry eye in a patient treated with the combination of PD-1 inhibitor sintilimab and multi-targeted receptor tyrosine kinase inhibitor (TKI) anlotinib. Case Description A 65-year-old woman with non-small cell lung cancer (NSCLC) and bone metastases, without pre-existing ocular conditions, experienced mild dry eye symptoms 1 month following treatment with sintilimab (200 mg q3w) in combination with anlotinib (12 mg q3w). Unrelieved dry eye symptoms occurred after the third cycle of chemotherapy, and she was diagnosed with dry eye syndrome. Subsequently, she received corneal protective lens, sodium hyaluronate eye drops, and prednisone treatment. Her corneal epithelial damage did not improve significantly, and within the following 2 months, her vision decreased in both eyes and progressed to bilateral corneal ulcers. Oral administration of sintilimab and anlotinib was interrupted, and treatments such as corticosteroids, anti-inflammatory drugs, and corneal repair were administered; however, both eyes presented with corneal subepithelial defect and corneal scarring. Due to a shortage of donors, no corneal transplantation surgery could be performed. Conclusions The development of corneal epithelial disorders in patients receiving target therapy and immunotherapy may not be reversed by reducing its dose. Although the condition is controlled with the use of glucocorticoids, some eye side effects cannot be cured. The timely detection and intervention of adverse effects of anti-tumor drugs by oncologists and ophthalmologists is critical for rational prescription. Ophthalmologists should be aware of eye side effects in patients using immunotherapy to ensure appropriate treatment and minimize potential eye complications such as dry eye, conjunctivitis, etc.

show abstract

Section: Discussionmentioning

confidence: 99%